Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02742246 · ClinicalTrials.gov registry record · NA

Efficacy and Mechanisms of CBT4CBT for Alcohol Use Disorders

A NA study, sponsored by Yale University.

Completed
Registry status
NA
Development phase
99
Enrollment target

NCT02742246: Completed NA study, sponsored by Yale University.

NCT02742246 is a NA study that has completed, run by Yale University. The registered enrollment target is 99 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02742246, a NA study, has completed, sponsored by Yale University.

COMPLETED
Registry status
NA
Development phase
99 participants
Enrollment target

Study Summary

Evaluate the efficacy of CBT4CBT and clinician-delivered CBT relative to standard treatment for reducing alcohol use

Primary Outcome

The Timeline Follow Back is a calendar-based questionnaire used to assess alcohol use-consumption variables and can be used to measure alcohol use over time. This outcome was updated upon results entry. Presented are the percent days abstinent from alcohol use.

Interventions

  • BEHAVIORAL Individual clinician-provided CBT
  • BEHAVIORAL CBT4CBT

Trial Details

FieldValue
Enrollment Target 99 participants
Start Date 2017-02-14
Est. Completion 2021-12-31
Phase NA
Yale University

1,492 total trials

What the finished NCT02742246 record still lists

NCT02742246 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).

The record links to 0 conditions, and to 2 interventions - of which Individual clinician-provided CBT is the first listed.

NCT02742246 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02742246 about?

NCT02742246 is a clinical study titled "Efficacy and Mechanisms of CBT4CBT for Alcohol Use Disorders". Evaluate the efficacy of CBT4CBT and clinician-delivered CBT relative to standard treatment for reducing alcohol use

What is the current status of trial NCT02742246?

This trial is currently completed. It is a NA study. The enrollment target is 99 participants. The study started on 2017-02-14. Estimated completion is 2021-12-31.

What interventions are being tested in trial NCT02742246?

The interventions under investigation include: Individual clinician-provided CBT (BEHAVIORAL), CBT4CBT (BEHAVIORAL).

Who is sponsoring clinical trial NCT02742246?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02742246's enrollment target sits among peer trials

99 920th of 2000 higher than 1,079 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03965234 · 99 participants · Phase 1

    Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

  • NCT04022616 · 99 participants

    Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

  • NCT04042844 · 99 participants · Phase 2

    A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

  • NCT04143724 · 99 participants · Phase 2

    Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02742246, the US trial registry maintained by the National Library of Medicine. NCT02742246 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.